Claire Mazumdar, Chief Executive Officer and Director of Bicara Therapeutics Inc., filed a Form 4 on August 12, 2026, reporting the exercise of stock options and a same-day sale of common stock on August 10, 2026, pursuant to a Rule 10b5-1 trading plan.

Key Highlights

  • Option exercise: Mazumdar exercised 10,000 stock options at an exercise price of $3.7898 per share on August 10, 2026.
  • Shares sold: 10,000 shares of common stock were disposed of at a weighted average price of $27.975 per share, with individual transactions ranging from $27.58 to $28.30, inclusive.
  • Post-transaction ownership: Following the transactions, Mazumdar directly beneficially owned 362,152 shares of common stock.
  • Rule 10b5-1 plan: Both transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.
  • Remaining derivative securities: Mazumdar holds 110,546 stock options with an exercise price of $3.7898 and an expiration date of April 5, 2033.

Bicara Therapeutics CEO Option Exercise and Share Sale Details

According to the filing, Claire Mazumdar, who serves as both Chief Executive Officer and Director of Bicara Therapeutics Inc. (NASDAQ:BCAX), conducted two related transactions on August 10, 2026. She exercised a stock option covering 10,000 shares of common stock at an exercise price of $3.7898 per share, temporarily bringing her direct beneficial ownership to 372,152 shares following that exercise.

The filing further reports that Mazumdar simultaneously disposed of 10,000 shares under transaction code "S" at a weighted average sale price of $27.975. The shares were sold in multiple transactions at prices ranging from $27.58 to $28.30, inclusive. The filing states that Mazumdar "undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price." After both transactions settled, her direct beneficial ownership stood at 362,152 shares.

The filing discloses that the underlying stock option vests "in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date," and carries an expiration date of April 5, 2033. Both the option exercise and the share sale were executed pursuant to a Rule 10b5-1 trading plan that Mazumdar adopted on March 31, 2026. The Form 4 was signed by Ryan Cohlhepp as Attorney-in-Fact on August 12, 2026.

What Was Disclosed

The filing documents the exercise of 10,000 stock options at $3.7898 per share and the sale of 10,000 common shares at a weighted average of $27.975, both occurring on August 10, 2026, under a pre-established Rule 10b5-1 plan, leaving Mazumdar with 362,152 shares and 110,546 remaining options.